Trimetazidine pills 20mg №30

Packaging

30 pieces

Mechanism of action

Trimetazidine has antianginal, coronarodilating, antihypoxic and hypotensive effects. Directly affecting the cardiomyocytes and neurons of the brain, optimizes their metabolism and function.

The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation).

Supports myocardial contractility, prevents a decrease in the intracellular content of adenosine triphosphate and phosphocreatine. Under conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of Calcium and sodium ions in cardiomyocytes, and normalizes the intracellular content of potassium ions.

Reduces intracellular acidosis and elevated phosphate levels due to myocardial ischemia and reperfusion. Interferes with the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic area, increases the duration of the electric potential,reduces the release of creatine phosphokinase from cells and the severity of ischemic myocardial damage.

When angina reduces the frequency of attacks, after 2 weeks of treatment increases exercise tolerance, reduced blood pressure drops. Reduces dizziness and tinnitus. When vascular pathology of the eye improves the functional activity of the retina.

Trimetazidine is rapidly and almost completely absorbed in the gastrointestinal tract. Bioavailability - 90%. The time to reach the maximum concentration in the blood plasma is 2 hours. The maximum concentration after a single dose of 20 mg of Trimetazidine is about 55 ng / ml. Communication with plasma proteins - 16%. Easily penetrates histohematogenous barriers. The half-life is 4.5-5 hours. Excreted by the kidneys (about 60% - unchanged).

Coronary heart disease: prevention of strokes (in combination therapy):
Chorioretinal vascular disorders
Vertigo of vascular origin
Cochleo-vestibular disorders of the ischemic nature (tinnitus, hearing loss).

Contraindications

Hypersensitivity to any component of the drug;
Renal failure (creatinine clearance below 15 ml / min);
Severe abnormal liver function;
Pregnancy;
Breastfeeding period:
Age up to 18 years (efficacy and safety have not been established).

Pregnancy and Breastfeeding

Taking the drug during pregnancy and lactation is contraindicated.

Dosage and Administration

The drug should be taken orally, during meals. The recommended dosage regimen is 1 pill (20 mg) 2-3 times a day (40-60 mg per day). The duration of the course of therapy is recommended by the doctor.

Adverse reactions

Allergic reactions (pruritus). Rarely: headache, feeling of palpitations; on the part of the digestive system - nausea, vomiting, gastralgia.

Special notes

Do not use for the relief of angina attacks! The drug is not indicated for the initial course of treatment of stable angina or myocardial infarction. If an attack of angina occurs, the therapy should be reviewed and adapted. The use of the drug does not affect the ability to drive and the performance of psychomotor reactions.

Storage conditions

Store in a dry, dark place at a temperature not exceeding 25 ° C. Keep out of the reach of children.